SANXING(SH:601567) Xin Lang Zheng Quan·2025-09-30 01:22Core Viewpoint - Samsung Medical's stock experienced a slight decline of 0.37% on September 29, with a trading volume of 576 million yuan, indicating a mixed market sentiment towards the company [1]. Financing Summary - On September 29, Samsung Medical had a financing buy-in amount of 56.18 million yuan, with a net financing purchase of 10.93 million yuan after repayments [1]. - The total financing and securities balance for Samsung Medical reached 377 million yuan, with the financing balance accounting for 1.09% of the circulating market value, indicating a high level compared to the past year [1]. - The company had a low short-selling balance of 2.02 million yuan, with a short-selling volume of 3,800 shares on the same day [1]. Business Performance - As of June 30, Samsung Medical reported a total of 29,000 shareholders, an increase of 76.91% from the previous period, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - For the first half of 2025, Samsung Medical achieved an operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%, and a net profit attributable to shareholders of 1.230 billion yuan, up 6.93% year-on-year [2]. Dividend Information - Since its A-share listing, Samsung Medical has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3].